PMA device
VENTANA PD-L1 (SP263) CDx Assay
Ventana Medical Systems, Inc. · Immunohistochemistry Assay, Antibody, Programmed Death-Ligand 1 (PLS, Class III) · First FDA decision May 18, 2016, newest Oct 23, 2024Cancer detection and genomic testingLung cancer and lung nodules
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
4
PMA pathway
Device trials
0
Naming "PD-L1 CDx"
MAUDE reports
0
Brand "PD-L1 CDx", since 2015
PubMed studies
0
Mentioning "PD-L1 CDx"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing VENTANA PD-L1 (SP263) CDx Assay
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 4 of 4 decisions filed under this name.
- VENTANA PD-L1 (SP263) CDx AssayPMA supplement
P160046-S019 · Decided Oct 23, 2024 · 323 days after receipt · Normal 180 Day Track
Device type: Immunohistochemistry assay, antibody, programmed death-ligand 1 (PLS) · Laboratory Medicine & Pathology
- VENTANA PD-L1(SP142) CDX ASSAYPMA supplement
P160002-S006 · Decided Jul 2, 2018 · 18 days after receipt · Normal 180 Day Track
Device type: Immunohistochemistry assay, antibody, programmed death-ligand 1 (PLS) · Laboratory Medicine & Pathology
- VENTANA PD-L1(SP142) CDX ASSAYPMA supplement
P160002-S001 · Decided Dec 21, 2016 · 111 days after receipt · Normal 180 Day Track No User Fee
Device type: Immunohistochemistry assay, antibody, programmed death-ligand 1 (PLS) · Laboratory Medicine & Pathology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "PD-L1 CDx", any status and sponsor, newest update first.
No registered device study names "PD-L1 CDx".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "PD-L1 CDx", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code PLS
35 reports: 34 malfunction, 1 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "PD-L1 CDx"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code PLS.
- PD-L1 IHC 22C3 pharmDxAgilent Technologies, Inc. · PMA 2026
- VENTANA PD-L1 (SP263) AssayVentana Medical Systems, Inc. · PMA 2023
- PD-L1 IHC 28-8 pharmDxAgilent Technologies, Inc. · PMA 2026
- PD-L1 Ihc 28-8 PharmdxDako North America, Inc. · PMA 2017
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.